Solifenacin
VESIcare
Cholinergic Muscarinic Antagonist
NADAC/unit
$0.1735
No Shortage
Tier 1: 43.8%
PA Req: 1.2%
17 Manufacturers
34 ANDAs
Solifenacin succinate tablets are indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
vs. brand VESIcare: Generic saves up to 98% per unit
Market Intelligence
2025-04-16 Class II Recall: Glenmark Pharmaceuticals Inc., USA
2025-04-16 Class II Recall: Glenmark Pharmaceuticals Inc., USA
Generic Manufacturers
ALEMBIC PHARMACEUTICALS LTDALKEM LABORATORIES LTDANNORA PHARMA PRIVATE LTDAUROBINDO PHARMA LTDBOSTAL LLCCHARTWELL RX SCIENCES LLCGLENMARK SPECIALTY SAJUBILANT GENERICS LTDMACLEODS PHARMACEUTICALS LTDMSN LABORATORIES PRIVATE LTDNOVITIUM PHARMA LLCQILU PHARMACEUTICAL CO LTDRISING PHARMA HOLDINGS INCSCIEGEN PHARMACEUTICALS INCTEVA PHARMACEUTICALS USAUNICHEM LABORATORIES LTDWATSON LABORATORIES INC
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.